|
1.
|
|
12 p, 1.2 MB |
Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy
/
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Sánchez, Olga (Vall d'Hebron Institut d'Oncologia) ;
Martínez, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Domínguez, Carmen (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Ruíz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ;
Céspedes, Maria Concepció (Hospital Universitari Vall d'Hebron) ;
Peñuelas, Ángeles (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Llurba, E (Institut d'Investigació Biomèdica Sant Pau) ;
Córdoba, Octavi (Institut d'Investigació Sanitària de les Illes Balears) ;
Universitat Autònoma de Barcelona
Anthracyclines and taxanes are being used as a standard treatment for breast cancer diagnosed during pregnancy. These chemotherapy regimens allow the continuation of pregnancy without delaying cancer treatment with relatively good maternal and neonatal outcomes. [...]
2021 -  10.3390/cancers13040923
Cancers, Vol. 13 (february 2021)
|
|
|
2.
|
|
8 p, 3.1 MB |
Lkb1 Loss Promotes Tumor Progression of BRAF V600E -Induced Lung Adenomas
/
González-Sánchez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martín-Caballero, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Flores, Juana María (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron) ;
Cortés, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Mares, Roso (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Barbacid, Mariano (Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid, Madrid, Spain) ;
Recio Conde, Juan Ángel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Aberrant activation of MAP kinase signaling pathway and loss of tumor suppressor LKB1 have been implicated in lung cancer development and progression. Although oncogenic KRAS mutations are frequent, BRAF mutations (BRAF V600E) are found in 3% of human non-small cell lung cancers. [...]
2013 - 10.1371/journal.pone.0066933
PloS one, Vol. 8 (june 2013)
|
|
|
3.
|
|
6 p, 916.0 KB |
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
/
De Mattos-Arruda, Leticia (Universitat Autònoma de Barcelona) ;
Mayor, Regina (Vall d'Hebron Institut d'Oncologia) ;
Ng, Charlotte K. Y. (Memorial Sloan Kettering Cancer Center) ;
Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ;
Martinez-Ricarte, Fran (Universitat Autònoma de Barcelona) ;
Torrejon, Davis (Vall d'Hebron Institut d'Oncologia) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Raventós, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Tang, Jiabin (Memorial Sloan Kettering Cancer Center) ;
Guerini-Rocco, Elena (Memorial Sloan Kettering Cancer Center) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Lois, Sergio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Marín, Oscar (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de la Cruz, Xavier (Institució Catalana de Recerca i Estudis Avançats) ;
Piscuoglio, Salvatore (Memorial Sloan Kettering Cancer Center) ;
Towers, Russel (Department of Surgery, Memorial Sloan Kettering Cancer Center) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona) ;
Carles, Joan (Vall d'Hebron Institut d'Oncologia) ;
Rodon, Jordi (Vall d'Hebron Institut d'Oncologia) ;
González-Cao, María (Quirón Dexeus University Hospital) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Felip, Enriqueta (Universitat Autònoma de Barcelona) ;
Sahuquillo Barris, Juan (Universitat Autònoma de Barcelona) ;
Berger, Michael F. (Memorial Sloan Kettering Cancer Center) ;
Cortés, Javier (Universitat Autònoma de Barcelona) ;
Reis-Filho, Jorge S. (Memorial Sloan Kettering Cancer Center) ;
Seoane Suárez, Joan (Universitat Autònoma de Barcelona)
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the genomic alterations present in tumours and has been used to monitor tumour progression and response to treatments. [...]
2015 - 10.1038/ncomms9839
Nature communications, Vol. 6 (november 2015)
|
|
|
4.
|
|
12 p, 5.0 MB |
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
/
Vicario, Rocio (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Zacarias-Fluck, Mariano (Vall d'Hebron Institut d'Oncologia) ;
Zhang, Junjie (Vall d'Hebron Institut d'Oncologia) ;
Martínez-Barriocanal, Águeda (Vall d'Hebron Institut d'Oncologia) ;
Navarro Jiménez, Alexandra (Hospital Universitari Vall d'Hebron) ;
Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Burgues, Octavio (Hospital Clínic Universitari (València)) ;
Lluch, Ana (Hospital Clínic Universitari (València)) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rubio, Isabel T. (Vall d'Hebron Institut d'Oncologia) ;
Marangoni, Elisabetta (Institut Curie) ;
Deeds, James (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma AG (Suïssa)) ;
Schlegel, Robert (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma AG (Suïssa)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Mosher, Rebecca (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma (Suïssa)) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. [...]
2015 - 10.1371/journal.pone.0129876
PloS one, Vol. 10 (june 2015)
|
|
|
5.
|
|
10 p, 621.9 KB |
Obesity and Breast Cancer : a Paradoxical and Controversial Relationship Influenced by Menopausal Status
/
García-Estévez, Laura (Centro de Investigación Biomédica en Red de Cáncer) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Pérez, Silvia (Breast Cancer Department, MD Anderson Cancer Center) ;
Calvo Plaza, Isabel (Breast Cancer Department, MD Anderson Cancer Center) ;
Gallegos, Isabel (Breast Cancer Department, MD Anderson Cancer Center) ;
Moreno-Bueno, Gema (MD Anderson International Foundation) ;
Universitat Autònoma de Barcelona
Breast cancer is the most common tumor in women worldwide, and an increasing public health concern. Knowledge of both protective and negative risk factors is essential for a better understanding of this heterogenous disease. [...]
2021 - 10.3389/fonc.2021.705911
Frontiers in Oncology, Vol. 11 (august 2021)
|
|
|
6.
|
|
0 p, 170.6 KB |
Commentary : SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
/
Di Cosimo, S. (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano) ;
Porcu, L. (Istituto di Ricerche Farmacologiche Mario Negri IRCCS) ;
Malfettone, Andrea (Medica Scientia Innovation Research (New Jersey, Estats Units d'Amèrica)) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Miceli, R. (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano. Department of Applied Research and Technological Development) ;
Universitat Autònoma de Barcelona
2020 - 10.3389/fonc.2020.01223
Frontiers in Oncology, Vol. 10 (july 2020) , p. 1223
|
|
|
7.
|
|
9 p, 1.7 MB |
Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design
/
Sampayo-Cordero, Miguel (Medica Scientia Innovation Research (MedSIR)) ;
Miguel-Huguet, Bernat (Hospital Universitari de Bellvitge) ;
Pérez-García, José (QuironSalud Group) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Guerrero-Zotano, Ángel L. (Vanderbilt University Medical Center) ;
Garde-Noguera, Javier (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Aguirre, Elena (Hospital Quirónsalud Zaragoza) ;
Holgado, Esther (Hospital Universitario Ramón y Cajal (Madrid)) ;
López-Miranda, Elena (Hospital Universitario Ramón y Cajal (Madrid)) ;
Huang, Xin (Pfizer Global Research and Development) ;
Malfettone, Andrea (Medica Scientia Innovation Research (MedSIR)) ;
Llombart-Cussac, Antonio (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Non-inferiority (NI) analysis is not usually considered in the early phases of clinical development. In some negative phase II trials, a post-hoc NI analysis justified additional phase III trials that were successful. [...]
2020 - 10.1016/j.conctc.2020.100678
Contemporary Clinical Trials Communications, Vol. 20 (november 2020)
|
|
|
8.
|
|
13 p, 6.8 MB |
Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
/
Prat, Aleix (Vall d'Hebron Institut d'Oncologia) ;
Adamo, Barbara (Vall d'Hebron Institut d'Oncologia) ;
Fan, Cheng (Lineberger Comprehensive Cancer Center, University of North Carolina) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Vidal, Maria (Vall d'Hebron Institut d'Oncologia) ;
Galván, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Palmer, Héctor G. ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Dawood, Shaheenah (Department of Medical Oncology, Dubai Hospital) ;
Rodón, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ;
Campo, Josep Maria Del (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). [...]
2013 - 10.1038/srep03544
Scientific reports (Nature Publishing Group), Vol. 3 (december 2013)
|
|
|
9.
|
|
14 p, 3.0 MB |
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
/
Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ;
Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Luque, Antonio (Vall d'Hebron Institut d'Oncologia) ;
Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ;
Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Dijcks, Fred A. (Preclinical R&D, The Netherlands) ;
Dokter, Wim H.A. (Preclinical R&D, The Netherlands) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. [...]
2020 - 10.3390/cancers12030670
Cancers, Vol. 12 (march 2020)
|
|
|
10.
|
|
30 p, 7.5 MB |
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
/
De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ;
Sammut, S.J. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Ross, E.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Bashford-Rogers, R. (Department of Medicine. University of Cambridge) ;
Greenstein, E. (Weizmann Institute of Science (Israel). Department of Immunology) ;
Markus, H. (Mayo Clinic Center for Individualized Medicine) ;
Morganella, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Teng, Y. (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ;
Maruvka, Y. (Massachusetts General Hospital (Boston)) ;
Pereira, B. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Rueda, O.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Chin, S.F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Contente-Cuomo, T. (Mayo Clinic Center for Individualized Medicine) ;
Mayor, R. (Centro de Investigación Biomédica en Red de Cáncer) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Ali, H.R. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Cope, W. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Tiezzi, D. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Dariush, A. (Institute of Astronomy. University of Cambridge) ;
Dias Amarante, T. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Reshef, D. (Weizmann Institute of Science (Israel). Department of Immunology) ;
Ciriaco, 0000-0002-1151-554X (Hospital Universitari Vall d'Hebron) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Vassiliou, G. (Wellcome Trust/MRC Cambridge Stem Cell Institute) ;
Getz, G. (Massachusetts General Hospital (Boston)) ;
Nik-Zainal, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Murtaza, M. (Mayo Clinic Center for Individualized Medicine) ;
Friedman, N. (Weizmann Institute of Science (Israel). Department of Immunology) ;
Markowetz, F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Caldas, C. (Cancer Research UK Cambridge Cancer Centre (Regne Unit)) ;
Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 - 10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
